We observed that mRNA expression of A3B and NF-κB components RELA and RELB, as well as an NF-κB gene signature42, were significantly increased in tumors exposed to EGFR TKI treatment, in particular at tumor progression with therapy (Extended Data Fig. 8h–k). The gene discussed is RELB; the disease is neoplasm.